Abstract
A series of both genetic and epigenetic factors have been implicated in the genesis and progression of prostate cancer. Recent evidence revealed that protein kinase C (PKC) isozymes play a crucial role in the control of cell proliferation and apoptosis in prostate cancer models, as well as in the transition from an androgen-dependent to an androgen-independent status. Indeed, PKCa and PKCd promote apoptosis in androgen-dependent prostate cancer cells. Due to the relevance of PKC isozymes in the control of cell cycle, both in G1/S and G2 / M, the elucidation of such complex intracellular networks using cellular and animal models has become of outmost importance. In this review, we present the current knowledge on the regulation of apoptosis and tumorigenicity by PKC isozymes and the functional roles of cell cycle regulators in prostate carcinogenesis. The development of animal models where overexpression of discrete PKCs or cell cycle regulators is targeted to the prostate will greatly contribute to the understanding of the molecular basis of the disease, and more importantly, it will have profound implications for the development of novel strategies for prostate cancer therapy.
Keywords: protein kinase c, pkc isozymes, prostate carcinogenesis, cell cycle, apoptosis, animal models, phorbol esters, androgen
Current Drug Targets
Title: Protein Kinase C and Prostate Carcinogenesis: Targeting the Cell Cycle and Apoptotic Mechanisms
Volume: 5 Issue: 5
Author(s): M. Veronica Gavrielides, Anita F. Frijhoff, Claudio J. Conti and Marcelo G. Kazanietz
Affiliation:
Keywords: protein kinase c, pkc isozymes, prostate carcinogenesis, cell cycle, apoptosis, animal models, phorbol esters, androgen
Abstract: A series of both genetic and epigenetic factors have been implicated in the genesis and progression of prostate cancer. Recent evidence revealed that protein kinase C (PKC) isozymes play a crucial role in the control of cell proliferation and apoptosis in prostate cancer models, as well as in the transition from an androgen-dependent to an androgen-independent status. Indeed, PKCa and PKCd promote apoptosis in androgen-dependent prostate cancer cells. Due to the relevance of PKC isozymes in the control of cell cycle, both in G1/S and G2 / M, the elucidation of such complex intracellular networks using cellular and animal models has become of outmost importance. In this review, we present the current knowledge on the regulation of apoptosis and tumorigenicity by PKC isozymes and the functional roles of cell cycle regulators in prostate carcinogenesis. The development of animal models where overexpression of discrete PKCs or cell cycle regulators is targeted to the prostate will greatly contribute to the understanding of the molecular basis of the disease, and more importantly, it will have profound implications for the development of novel strategies for prostate cancer therapy.
Export Options
About this article
Cite this article as:
Gavrielides Veronica M., Frijhoff F. Anita, Conti J. Claudio and Kazanietz G. Marcelo, Protein Kinase C and Prostate Carcinogenesis: Targeting the Cell Cycle and Apoptotic Mechanisms, Current Drug Targets 2004; 5 (5) . https://dx.doi.org/10.2174/1389450043345380
DOI https://dx.doi.org/10.2174/1389450043345380 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Advances in Human Cytochrome P450 and Personalized Medicine
Current Drug Metabolism Cyclic Peptides that Govern Signal Transduction Pathways: From Prokaryotes to Multi-Cellular Organisms
Current Topics in Medicinal Chemistry Significance of P2X7 Receptor Variants to Human Health and Disease
Recent Patents on DNA & Gene Sequences Cancer T Cell Immunotherapy with Bispecific Antibodies and Chimeric Antigen Receptors
Recent Patents on Anti-Cancer Drug Discovery Preface [Hot topic: Apoptosis and Cancer Therapeutics (Guest Editor: M. Saeed Sheikh)]
Current Cancer Drug Targets Role of CD73 in Disease: Promising Prognostic Indicator and Therapeutic Target
Current Medicinal Chemistry Vagotomy and Gastric Tumorigenesis
Current Neuropharmacology Cachexia and Herbal Medicine: Perspective
Current Pharmaceutical Design Biotransformation of Silybin and its Congeners
Current Drug Metabolism The p35 Family of Apoptosis Inhibitors
Current Genomics MicroRNA-136 Promotes Vascular Muscle Cell Proliferation Through the ERK1/2 Pathway by Targeting PPP2R2A in Atherosclerosis
Current Vascular Pharmacology Meet Our Editorial Board Member:
Current Medicinal Chemistry Subject Index To Volume 1
Recent Patents on Anti-Cancer Drug Discovery Recent Patents in the Field of Radioprotector Development: Opportunities and Challenges
Recent Patents on Biotechnology Immuno-Modulatory Properties of a Quinolin-2-(1H)-on-3-Carboxamide Derivative: Relevance in Multiple Sclerosis
Recent Patents on CNS Drug Discovery (Discontinued) Sex Steroid Hormone Determination of the Maternal Brain: Effects Beyond Reproduction
Mini-Reviews in Medicinal Chemistry Prospects of miRNA-Based Therapy for Pancreatic Cancer
Current Drug Targets Recent Advances in Registration Methods for MRI-TRUS Fusion Image-Guided Interventions of Prostate
Recent Patents on Engineering Early Life Programming of Obesity: The Impact of the Perinatal Environment on the Development of Obesity and Metabolic Dysfunction in the Offspring.
Current Diabetes Reviews Overview of Current Immunotherapies Targeting Mutated KRAS Cancers
Current Topics in Medicinal Chemistry